IN8bio (NASDAQ:INAB – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.
Risk and Volatility
IN8bio has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
Profitability
This table compares IN8bio and Cadrenal Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IN8bio | N/A | -147.21% | -108.63% |
| Cadrenal Therapeutics | N/A | -279.50% | -204.46% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IN8bio | 1 | 1 | 1 | 0 | 2.00 |
| Cadrenal Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
IN8bio presently has a consensus target price of $92.00, indicating a potential upside of 4,025.56%. Cadrenal Therapeutics has a consensus target price of $32.00, indicating a potential upside of 331.85%. Given IN8bio’s higher possible upside, analysts plainly believe IN8bio is more favorable than Cadrenal Therapeutics.
Earnings & Valuation
This table compares IN8bio and Cadrenal Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IN8bio | N/A | N/A | -$30.44 million | ($5.45) | -0.41 |
| Cadrenal Therapeutics | N/A | N/A | -$10.65 million | ($8.01) | -0.93 |
Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
92.1% of IN8bio shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 15.5% of IN8bio shares are owned by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
IN8bio beats Cadrenal Therapeutics on 6 of the 9 factors compared between the two stocks.
About IN8bio
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.
